ACT1

ACT1 is a peptide that targets endogenous Cx43 by stabilizing its activity at gap junctions. ACT1 stabilizes gap junction intercellular communication in breast cancer cells. ACT1 enhances the activity of Tamoxifen and Lapatinib (HY-50898) in breast cancer. ACT1 can be used for breast cancer research[1].

895547-36-1

12352209

Gap Junction Protein

Cytoskeleton

Cancer

O=C(N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC4=CC=CC=C4)C(N5[C@@H](CCC5)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N6[C@@H](CCC6)C(N[C@@H](CC7=CNC8=CC=CC=C78)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N9[C@@H](CCC9)C(N[C@@H](CCCNC(N)=N)C(N%10[C@@H](CCC%10)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N

C150H238N48O34

3257.80

[1]Grek CL, et al. Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer. 2015 Apr 3;15:296.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11197/

Peptides

No Development Reported